

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended): A bactericidal/permeability-increasing protein (BPI) deletion analog consisting of amino acid residues 10 through 193 of mature human BPI (SEQ ID NO:2), wherein a cysteine residue at position 132 is replaced by a different amino acid.

Claim 2 (Original): The BPI deletion analog of claim 1 wherein the amino acid replacing said cysteine residue is a non-polar amino acid selected from the group consisting of alanine and serine.

Claim 3 (Original): The BPI deletion analog of claim 1 wherein the cysteine residue at position 132 is replaced by alanine.

Claim 4 (Currently Amended): [[A]] An isolated polynucleotide encoding the BPI deletion analog of claim 1.

Claim 5 (Currently Amended): [[A]] An isolated polynucleotide encoding the BPI deletion analog of claim 3.

Claim 6 (Currently Amended): The polynucleotide of claim 4 further comprising the twenty-seven amino acid leader sequence of BPI (amino acid residues -27 through -1 of SEQ. ID NO: 2).

Claim 7 (Original): The polynucleotide of claim 4 which is a DNA.

Claim 8 (Original): An expression vector comprising the DNA according to claim 7.

Claim 9 (Original): A host cell stably transformed or transfected with the DNA of claim 7 in a manner allowing expression in said host cell of said polypeptide deletion analog.

Claim 10 (Original): A eukaryotic host cell according to claim 9.

Claim 11 (Original): The host cell of claim 10 which is a CHO cell.

Claim 12 (Original): A method for producing a BPI deletion analog polypeptide comprising growing a host cell according to claim 9 in a suitable culture medium and isolating said polypeptide from said host cell or said culture medium.

Claim 13 (Original): The polypeptide product of the method of claim 12.

Claim 14 (Original): A composition comprising the BPI deletion analog of claim 1 and a pharmaceutically-acceptable diluent, adjuvant, or carrier.

Claim 15 (Original): A composition comprising the BPI deletion analog of claim 3 and a pharmaceutically-acceptable diluent, adjuvant, or carrier.

Claim 16 (Original): A composition comprising the BPI deletion analog of claim 13 and a pharmaceutically-acceptable diluent, adjuvant, or carrier.

Claim 17 (Currently Amended): ~~An improved A~~ method of administering a BPI protein product to a subject comprising administering the composition of claim 14 to said subject.

Claim 18 (Currently Amended): ~~An improved A~~ method of administering a BPI protein product to a subject comprising administering the composition of claim 15 to said subject.

Claim 19 (Currently Amended): ~~An improved A~~ method of administering a BPI protein product to a subject comprising administering the composition of claim 16 to said subject.